Showing paper detailed information
Citation Information
Sci Rep. 2015 Sep 25;5:14089. doi: 10.1038/srep14089.
In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging.
Li T, He J, Mao X, Bi Y, Luo Z, Guo C, Tang F, Xu X, Wang X, Wang M, Chen J, Abliz Z.
Analytical methods | ||
|---|---|---|
| Comparative study | #1 | |
| Chromatography | LC | |
| Ion source | AFADESI | |
| Positive/Negative mode | both | |
| Mass analyzer | Q-Orbitrap, Q-TOF | |
| Identification level | MS/MS | |
Sample information | ||
|---|---|---|
| Comparative study | #1 | |
| Country | China | |
| Specimen | tissue | |
| Marker function | diagnosis | |
| Participants(Case) | Cancer type | adenocarcinoma, squamous cell carcinoma |
| Stage | – | |
| Number | 52 | |
| Gender (M,F) | – | |
| Mean age (range) (M,F) | – | |
| Smoking status | – | |
| Participants(Control) | Type | tumor vs. adjacent normal tissue |
| Number | 21 | |
| Gender (M,F) | – | |
| Mean age (range) (M,F) | – | |
| Smoking status | – | |
Data processing and metabolite identification | |
|---|---|
| Data processing software | Markerview (AB SCIEX) |
| Database search | LIPID MAPS, Massbank, HMDB, METLIN |
Statistical analysis | |
|---|---|
| Differential analysis method | t-test, PLS-DA, OPLS-DA |
| Classification method | ROC curve analysis |
| Survival analysis method | – |
Lung cancer-related metabolites identified in the paper
| Metabolite | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
|---|---|---|---|---|---|---|---|
| betaine | – | – | – | – | – | – | 2.55 |
| choline | V | – | – | – | – | – | 14.00 |
| L-carnitine | – | – | – | – | – | – | 3.72 |
| PC(16:0/18:1) | – | – | – | – | – | – | 14.08 |
| PC(16:0/18:1) | – | – | – | – | – | – | 13.36 |
| PC(16:0/18:2) | – | – | – | – | – | – | 8.58 |
| PC(16:0/18:2) | – | – | – | – | – | – | 6.35 |
| PC(16:0/20:4) | V | – | – | – | – | – | 6.23 |
| PC(18:0/18:1) | – | – | – | – | – | – | 8.36 |
| PC(18:0/18:2) | – | – | – | – | – | – | 8.83 |
| PC(18:1/18:1) | – | – | – | – | – | – | 8.21 |
| PC(18:1/20:3) | V | – | – | – | – | – | 5.89 |
| PC(32:1) | – | – | – | – | – | – | 7.32 |
| PC(32:1) | – | – | – | – | – | – | 5.06 |
| PC(34:0) | – | – | – | – | – | – | 8.94 |
| PC(34:1) | V | – | – | – | – | – | 9.24 |
| PC(36:1) | – | – | – | – | – | – | 6.47 |
| PC(36:3) | V | – | – | – | – | – | 7.05 |
| PC(38:2) | V | – | – | – | – | – | 5.13 |
| PC(O-16:0/18:1) | – | – | – | – | – | – | 5.74 |
| PC(O-34:1) | – | – | – | – | – | – | 5.11 |
| PC(P-18:0/18:0) | – | – | – | – | – | – | 6.78 |
| PC(P-34:1) | – | – | – | – | – | – | 3.37 |
| proline | – | – | – | – | – | – | 2.01 |
| Metabolite | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
|---|---|---|---|---|---|---|
| betaine | – | – | – | – | – | – |
| choline | V | – | – | – | – | – |
| L-carnitine | – | – | – | – | – | – |
| PC(16:0/18:1) | – | – | – | – | – | – |
| PC(16:0/18:1) | – | – | – | – | – | – |
| PC(16:0/18:2) | – | – | – | – | – | – |
| PC(16:0/18:2) | – | – | – | – | – | – |
| PC(16:0/20:4) | V | – | – | – | – | – |
| PC(18:0/18:1) | – | – | – | – | – | – |
| PC(18:0/18:2) | – | – | – | – | – | – |
| PC(18:1/18:1) | – | – | – | – | – | – |
| PC(18:1/20:3) | V | – | – | – | – | – |
| PC(32:1) | – | – | – | – | – | – |
| PC(32:1) | – | – | – | – | – | – |
| PC(34:0) | – | – | – | – | – | – |
| PC(34:1) | V | – | – | – | – | – |
| PC(36:1) | – | – | – | – | – | – |
| PC(36:3) | V | – | – | – | – | – |
| PC(38:2) | V | – | – | – | – | – |
| PC(O-16:0/18:1) | – | – | – | – | – | – |
| PC(O-34:1) | – | – | – | – | – | – |
| PC(P-18:0/18:0) | – | – | – | – | – | – |
| PC(P-34:1) | – | – | – | – | – | – |
| proline | – | – | – | – | – | – |
Paper graphical summary
